Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments

Journal of Neuroscience Research

Volumn 53, Issue 5, 1998, Pages 593-604

  Tang, Yu Ping ^a   Ma, Yun Li ^a   Chao, Chih Chang ^b   Chen, Kai Yi ^a   Lee, Eminy H Y ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

( ) deprenyl; 1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Gene expression; Glial cell line derived neurotrophic factor; GM1 ganglioside; Melatonin; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; GANGLIOSIDE GM1; GLUTATHIONE PEROXIDASE; MELATONIN; MESSENGER RNA; NEUROTROPHIC FACTOR; SELEGILINE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN PROTECTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; GLIA CELL; INTRACEREBRAL DRUG ADMINISTRATION; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; CELL LINE; DOPAMINE; G(M1) GANGLIOSIDE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE PEROXIDASE; LIPID PEROXIDATION; MALE; MELATONIN; MONOAMINE OXIDASE; NEOSTRIATUM; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SELEGILINE; SUPEROXIDE DISMUTASE;

EID: 0001155209     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19980901)53:5<593::AID-JNR9>3.0.CO;2-4     Document Type: Article

References (57)

1. Acuna-Castroviejo D, Coto-Montes A, Gaia-Monti M, Ortiz GG, Reiter RJ (1997): Melatonin is protective against MPTP-induced striatal and hippocampus lesions. Life Sci 60:23-29.
2. Ansari KS, Yu PH, Kruck TP, Tatton WG (1993): Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: Stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13:4042-4053.
3. Bradford MM (1976): Rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Carrillo MC, Kanai S, Nokubo M, Kitani K (1991): (-)-Deprenyl induces activities of both Superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48:517-517.
5. Choi-Lundberg DL, Bohn MC (1995): Ontogency and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Dev Brain Res 85:80-88.
6. Chomczynski P, Sacchi N (1987): Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem 162:156-159.
7. Clow A, Hussain T, Glover V, Sandier M, Dexter DT, Walker M (1991): (-)-Deprenyl can induce soluble Superoxide dismutase in rat striata. J Neural Transm 6:77-80.
8. Engele J, Franke B (1996): Effects of glial cell line-derived neurotrophic factor (GDNF) on dopaminergic neurons require concurrent activation of cAMP-depcndent signaling pathways. Cell Tissue Res 286:235-240.
9. Fadda E, Negro A, Facci L, Skaper SD (1993): Ganglioside GM1 cooperates with brain-derived neurotrophic factor to protect dopaminergic neurons from 6-hydroxydaopmine-induced degeneration. Neurosci Lett 159:147-150.
10. Ferrari G, Greene LA (1996): Prevention of neuronal apoptotic death by neurotrophic agents and ganglioside GM1: Insights and speculations regarding a common mechanism. Perspect Dev Neurobiol 3:94-100.
11. Flohe L, Gunzler WA (1984): Assays of glutathione peroxidase. Methods Enzymol 105:114-121.
12. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996): Functional recovery in Parkinsonian monkeys treated with GDNF. Nature 380:252-255.
13. Heinonen EH, Lammintausta R (1991): A review of the pharmacology of selegiline. Acta Neurol Scand 84(Suppl 136):44-59.
14. Herrero MT, Perez-Otano I, Oset C, Kastner A, Hirsch EC, Agid Y, Luquin MR, Obeso JA, Rio JD (1993): GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience 56:965-972.
15. Hirsch E, Graybiel A, Agid Y (1988): Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348.
16. Hou JGG, Lin LFH, Mytilineou C (1996): Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-1-4-phenylpyridinium. J Neurochem 66: 74-82.
17. + toxicity: Role of BDNF gene expression. Mol Brain Res 41:16-26.
18. Jacobowitz D, Burns R, Chiueh CC, Irwin J (1984): N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey. Psychopharmacol Bull 20:416-423.
19. Jansen JG, Vrieling H, van Zealand A, Mohn G (1992): The gene encoding hypoxanthine-guanine phosphoribosyltransferase as target for mutational analysis: PCR cloning and sequencing of the cDNA from the rat. Mutat Res 266:105-116.
20. Kearns CM, Gash DM (1995): GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672:104-111.
21. Kindt MV, Youngster SK, Sonsalla PK, Duvoisin RC, Heikkila RE (1988): Role of monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal neurotoxicity of the MPTP analog, 2′-Me-MPTP. Eur J Pharmacol 146:313-318.
22. Knoll J (1989): The pharmacology of selegiline ((-)-deprenyl). New Aspects Acta Neurol Scand 126:83-91.
23. Lapchak PA, Miller PJ, Jiao S, Araujo DM, Hilt D, Collins F (1996): Biology of glial cell line-derived neurotrophic factor (GDNF): Implication for the use of GDNF to treat Parkinson's disease. Neurodegeneration 5:197-205.
24. Lapchakk PA, Gash DM, Jiao S, Miller PJ, Hilt D (1997): Glial cell line-derived neurotrophic factor: A novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Exp Neurol 144:29-34.
25. Ledeen R (1985): Gangliosides of the neuron. Trends Neurosci 5:169-174.
26. Lee EHY, Yang YL, Chia LG, Kuo JS (1994): Interactions among deprenyl, clorgyline and 1-methyl-4-phnyl-1,2,3,6-tetrahydropyidineon catecholamines in mice. Neurosci Lett 165:149-152.
27. +-ATPase after nigrostriatal transection. Brain Res 377:292-297.
28. Lm LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993): GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
29. Lin LF, Zhang TJ, Collins F, Armes LG (1994): Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor. J. Neurochem 63:758-768.
30. Lindner M, Winn S, Baetge E, Hammang J, Gentile F, Doherty E, McDermott P, Frydel B, Ullman M, Schallen T, Emerich D (1995): Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and Parkinsonian symptoms. Exp Neurol 132:62-76.
31. Lowe T, Sharefkin J, Yang S, Sieffenbach C (1990): A computer program for selection of oligonucleotide primers for polymerase chain reaction. Nucleic Acids Res 18:1757-1761.
32. Magyar K, Szende B, Lengyel J, Tekes K (1996): The pharmacology of B-type selective monoamine oxidase inhibitors: milestones in (-)-deprenyl research. J Neural Transm 48(Suppl)8:29-43.
33. Mason I (1996): The GDNF receptor: Recent progress and unanswered questions. Mol Cell Neurosci 8:112-119.
34. Misra HP, Fridovich I (1972): The role of Superoxide anion in the autoxidation of epinephrine and a simple assay for Superoxide dismutase. J Biol Chem 247:3170-3175.
35. Nagai Y, Tsuji S (1988) Cell biological significance of gangliosides in neural differentiation and development. In Ledenn RW, Hogan EL, Tettamanti G, Yates AJ, and Yu KK (eds): "New Trends in Ganglioside Research: Neurochemical and Neuroregenerative Aspects." New York: Springer-Verlag, pp 329-350.
36. Parkinson Study Group (1993a) A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Annals Neurol 33:350-356.
37. Parkinson Study Group (1993b) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl J Med 328:176-183.
38. Peat M, Gibb J (1983): High performance liquid Chromatographic determination of indoleamines, dopamine and norepinephrine in rat brain with fluorimetric detection. Anal Biochem 128:275-280.
39. Pochon NA, Menoud A, Tseng JL, Zurn AD, Aebischer P (1997): Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization. Eur J Neurosci 9:463-471.
40. Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC, Barlow-Walden LR (1994): Melatonin: A highly potent endogenous radical scavenger. Ann NY Acad Sci 738:419-420.
41. Reiter RJ (1996): The indoleamine melatonin as a free radical scavenger, electron donor, and antioxidant. In Filippini GA, Costa CVL, and Bertazzo A (eds): "Recent Advances in Tryptophan Research." New York: Plenum Press, pp 307-313.
42. Reiter RJ, Melchiorri D, Sewerynek E, Poeggeler B, Barlow-Ealden LR, Chuang JI, Ortiz GG, Acuna-Castroviejo D (1995): A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 18:1-11.
43. Sabel BA, Dunbar GL, Butler WM, Stein DG (1985): GM1 gangliosides stimulate neuronal reorganization and reduce rotation and reduce rotational asymmetry after hemitransections of the nigro-striatal pathway. Exp Brain Res 60:27-37.
44. Schneider JS, DiStefano L (1995): Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments. Brain Res 674:260-264.
45. Schneider J, Yuwiler A, Markham C (1987): Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res 411:144-150.
46. Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, DiStefano L (1992): Recovery from experimental Parkinsonism in primates with GM1 ganglioside treatment. Science 256:843-846.
47. Seniuk NA, Henderson JT, Tatton WG, Roder JC (1994): Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J Neurosci Res 37:278-286.
48. Shults CW, Kimber T, Martin D (1996): Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport 7:627-631.
49. Skaper SD, Leon A, Toffano G (1989): Ganglioside function in the development and repair of the nervous system. From basic science to clinical application. Mol Neurobiol 3:173-199.
50. Springer JE, Mu X, Bergmann LW, Trojanowski JQ (1994): Expression of GDNF mRNA in rat and human nervous tissue. Exp Neurol 127:167-170.
51. Tan DX, Poeggeler B, Reiter RJ, Chen LD, Chen S, Manchester LC, Barlow-Walden LR (1993): The pineal hormone melatonin inhibits DNA adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett 70:65-71.
52. Thomas CE, Huber EW, Ohlweiler DF (1997): Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72, 974A: Implication for protection of biological substrates. Free Radical Biol Med 22:733-737.
53. Toffano G, Savoini GE, Moroni F, Lombardi G, Calza L, Agnati LF (1983): GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system. Brain Res 261:163-166.
54. Tomac A, Lindqvist E, Lin LFH, Ogren SO, Young D, Hoffer BJ, Olson L (1995a): Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339.
55. Tomac A, Widenfalk J, Lin LF, Kohno T, Ebendal T, Hoffer BJ, Olson L (1995b): Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci USA 92:8274-8278.
56. Wu RM, Murphy DL, Chiueh CC (1996): Suppression of hydroxyl radical formation and protection of nigral neurons by 1-deprenyl (selegiline). Ann NY Acad Sci 786:379-390.
57. 14C-deprenyl. J Neural Transm 43:199-208.